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Abstract
Background: The commercially available urine LAM strip test, a point-of-care tuberculosis (TB) assay, requires
evaluation in a primary care setting where it is most needed. There is currently inadequate data to guide
implementation in TB and HIV-endemic settings.
Methods: Adult HIV-infected outpatients with suspected pulmonary TB able to self-expectorate sputum from four
primary clinics in South Africa, Zambia and Tanzania underwent diagnostic evaluation [sputum smear microscopy,
Xpert-MTB/RIF, and culture (reference standard)] as part of a prospective parent study. Urine LAM testing (grade-2
cut-point) was performed on archived samples. Performance characteristics of LAM alone or in combination with
sputum—based diagnostics were evaluated. Potential impact on 2 and 6-month morbidity (TBscore), patient
dropout rates, and prognosis (death/ loss to follow-up) were evaluated.
Results: Among 583 participants with suspected TB that were HIV-infected or refused testing, the overall LAM
sensitivity (95 % CI; n/N) and in the CD4 ≤ 100 cells/mm3 sub-group was 22.7 % (16.6-28.7; 41/181) and 30.4 %
(17.1-43.7; 14/46), respectively. Overall specificity was 93.0 % (90.5-95.6; 361/388). Amongst culture-positive TB cases,
adjunctive LAM testing did not improve the sensitivity of either sputum Xpert-MTB/RIF [78.2 % (69.8-86.7; 72/92)
versus 76.1 % (67.4-84.8; 70/92), p = 0.7] or smear-microscopy [56.2 % (45.9-66.5; 50/89) versus 43.8 % (33.5-54.1; 39/
89), p = 0.1). Clinic-based LAM, as an adjunct to either smear microscopy or Xpert MTB/RIF same-day testing, would
neither have decreased patient dropout, nor increased same-day treatment initiation in this clinical setting where
same-day chest radiography was available. LAM positivity was associated with 6-month lost-to-follow-up/death
(AOR 4.4; p = 0.002) but not TBscore (at baseline or change in TBscore 2-months post-treatment) (p = 0.17).
Conclusions: In African HIV-TB co-infected outpatients able to self-expectorate sputum LAM had limited sensitivity
even at low CD4 counts, and offered no significant incremental diagnostic yield over Xpert-MTB/RIF or smear
microscopy. In primary care clinics with chest radiography and where empiric TB treatment is common, LAM seems
unlikely to improve rates of same-day treatment initiation and patient dropout, however, the ability of LAM to
identify patients at high risk of death or lost-to-follow-up may offer important prognostic value.
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Background
Of the estimated 8.6 million active tuberculosis (TB)
cases globally an estimated three million cases remained
either undiagnosed or unreported [1]. Thus, tests and
technologies that allow rapid, accurate, point-of-care
(POC) diagnosis represent an unmet need and are pro-
jected to substantially reduce the global TB burden [2,
3]. An increasing number of high TB/HIV burden set-
tings are implementing frontline Xpert MTB/RIF testing
for HIV-infected patients with suspected TB [4–6], al-
though sputum smear microscopy remains the frontline
TB diagnostic tool in the majority of resource-poor high
burden settings. Used at the POC, Xpert MTB/RIF can
decrease dropout rates (patients TB-positive but not
returning to initiate treatment) and time-to-treatment
initiation [5, 7]. However, sensitivity in sputum is re-
duced in HIV-infected patients [8] and is also subopti-
mal in induced sputum samples [9]. These and other
considerations including infrastructure and electricity re-
quirements means that countries remain interested in
simple low-cost non-sputum based POC diagnostic tools
for both pulmonary and extrapulmonary TB diagnosis.
In 2013, the Alere Determine™ TB LAM Ag lateral
flow strip test (Alere, USA, www.alerehiv.com; referred
to as LAM from this point forward) became the first
commercially available bedside urine test for TB diagno-
sis in HIV co-infected patients with results available
within 25 minutes using just 60ul of urine [10]. To date,
diagnostic accuracy studies of urine LAM have been
largely single centre [11–13]. Tested patient populations
have been heterogeneous (patients with extrapulmonary
TB, those unable to spontaneously provide a sputum
sample for TB diagnostic testing, or hospitalised pa-
tients) [14] and the incremental value of LAM over spu-
tum smear microscopy or Xpert MTB/RIF has thus been
variable [11–17]. Nevertheless, POC tests like urine
LAM require evaluation in a primary care settings where
they are likely to have most impact and where more
than 90 % of the TB case load is first encountered. How-
ever, there are limited data to guide implementation in
such settings where POC TB tests are most needed. Fur-
thermore, the incremental value of LAM over tests like
Xpert MTB/RIF, if any, has hardly been studied in HIV
endemic primary care settings. There are also limited
published data about the potential impact of LAM on
morbidity, same-day treatment initiation, patient drop-
out rates and prognosis [18, 19].
In this study we sought to provide multicentre compara-
tive accuracy and extrapolate impact data of adjunctive
LAM testing in the setting where the overwhelming major-
ity of individuals with presumptive pulmonary TB present
(out-patient primary care clinics). These data are needed
to make a definitive recommendation about the use of
LAM in this key patient population. We hypothesised
that in out-patients able to self-expectorate sputum for
sputum-based diagnostics, LAM would have very limited
incremental utility. We therefore tested the urine for LAM
positivity in a cohort of 583 HIV-infected patients with
suspected pulmonary TB who formed part of a parent ran-
domised controlled trial comparing Xpert MTB/RIF with
same-day smear microscopy in primary care clinics of
three sub-Saharan African countries [5]. All the partici-
pants provided two expectorated sputa and urine sample.
Methods
Design and study population
This cross-sectional accuracy study was nested within a
randomised, parallel-arm, multicentre trial, to evaluate
the impact of point-of-treatment Xpert MTB/RIF testing
with same-day smear microscopy. Patients were enrolled
between 12 April 2011 and 1 October 2012. Outpatients
≥18 years that presented to periurban primary-care TB
clinics with attached DOTS facilities and microscopy
laboratories in Cape Town and Durban (South Africa;
laboratory centrally-located), Harare (Zimbabwe), Lusaka
(Zambia), and Mbeya (Tanzania) were consecutively en-
rolled after informed consent. Five Human Research Eth-
ics Committees (HREC) approved the study (University of
Cape Town HREC, University of Zambia Biomedical Re-
search Ethics Committee, Mbeya Medical Research Ethics
Committee and Medical Research Coordinating Commit-
tee of the National Institute for Medical Research, Medical
Research Council Durban HREC). Inclusion criteria in-
cluded: i) symptom(s) of pulmonary TB according to pre-
defined WHO criteria [20, 21] (see online supplementary
methods for further details), ii) the ability to spontan-
eously expectorate two spot sputum specimens with a
volume of ≥1 ml each, and exclusion criteria included: i)
failure to obtain informed consent and ii) initiation of
anti-TB treatment in the previous 60 days. In this sub-
study, HIV-uninfected patients were excluded from the
analysis. Patients refusing voluntary counselling and test-
ing for HIV (3 %) where considered “positive” and included
in the LAM analysis as this would occur in routine clinical
practice given the very high (>50 %) incidence of HIV co-
infection amongst new TB cases in these endemic coun-
tries. A further detailed description of RCT methodology
including description of each primary care clinic site is
available with the published manuscript of the parent
study [5].
Sample collection and processing
Each patient had at least two spot expectorated sputa
collected sequentially at recruitment. Nurses visually
inspected expectorated sputum samples and estimated
the volume using standards of known volume. Patients
randomised to the smear microscopy study arm received
two same-day sputum smears for acid-fast bacilli and
Peter et al. BMC Infectious Diseases  (2015) 15:262 Page 2 of 12
one arbitrarily selected specimen also underwent culture.
Patients in the Xpert MTB/RIF arm received nurse-
performed clinic-based Xpert MTB/RIF testing and the
other specimen was sent for culture. All patients were
asked to provide a spontaneously voided urine sample
(10–30ml) into a sterile receptacle. Urine was trans-
ferred to the laboratory within 4 hours and frozen at -20
degrees for later batch testing. Urine samples were col-
lected in all parent study sites except Zimbabwe where
urine biobanking was not possible.
Clinical management and follow-up
Patients were enrolled and initially reviewed by research
nursing staff. They were offered voluntary testing and
counselling for HIV at recruitment, and received a chest
radiograph while awaiting their rapid TB test result.
TB-related morbidity was assessed at enrolment and
during 2- and 6-month follow-up using the previously
validated TBscore [22] (Additional file 1 Table S1 in the
online supplement). Patients were referred to the local
DOTS programme office at the same clinic for the initi-
ation of anti-TB treatment if any positive result from ei-
ther smear microscopy, Xpert MTB/RIF, or TB culture
result was obtained. Smear-or Xpert MTB/RIF negative
patients were referred to clinical staff for review together
with their chest radiographs and as part of the routine
clinic workflow. The WHO guidelines for the treatment
of smear-negative TB [21] are routinely used at each clinic.
Doctors who were not part of the study team and rou-
tinely visited each facility twice a week initiated the treat-
ment of smear- or Xpert MTB/RIF-negative patients.
Follow-up was conducted for all study patients by research
staff at 2- and 6-months post randomisation (within a
range of 14 days before and after both time points). Pa-
tients were considered lost-to-follow up if they were not
contactable despite multiple attempts at telephonic con-
tact and a community healthcare worker tracing.
Diagnostic test procedures
Liquid TB culture (Bactec MGIT; BD Microbiology
Systems, USA) was performed in central laboratories on
sputum decontaminated using N-acetyl-L-cysteine–NaOH.
Front-loaded, same-day smear microscopy was performed
on-site by a technician employed by the programme in a
laboratory attached to the healthcare facility, except in
South Africa where it was performed at a centralised la-
boratory. Fluorescence smear microscopy was performed
on concentrated samples with auramine-O staining at all
sites except Mbeya, Tanzania where concentrated samples
underwent ZN-staining and light microscopy. Patients
were classified as having smear-positive tuberculosis on
the basis of at least one scanty smear (1–9 bacilli per 100
fields [1000× for light microscopy and 400× for fluores-
cence microscopy]).
Trained staff, including clinical and laboratory staff,
according to the manufacturer recommendations on un-
processed thawed urine specimens stored at -20 degrees
for not longer than 18 months, performed LAM strip
tests. Two independent readers, blinded to reference test
results and clinical outcomes, graded (0–5 according
to the colour band intensity) each strip after 25–35
minutes using the pre-January 2014 manufacturer’s ref-
erence card (see Additional file 1 Figure S1A in supple-
ment). Where results between the two independent
readers were discordant, a third consensus reader graded
the LAM strip, and this consensus read was used in the
analysis. Further details on the reading of LAM strip
tests and the reference cards are provided in the online
supplement. LAM strip results were neither provided to
the clinicians caring for patients nor were they used for
treatment decisions.
Statistical analyses
The reference standard for the primary analysis of diag-
nostic accuracy was a single sputum liquid culture for
Mycobacterium tuberculosis. An additional analysis is
provided in the online supplement with culture-negative
clinical-TB cases considered reference standard positive
given the acknowledged limitation of a single sputum
TB culture to diagnose TB in HIV co-infection. The study
was powered (75–100 % at 95 % confidence interval) to
detect differences in diagnostic accuracy between LAM,
Xpert MTB/RIF and smear, alone or in combination, for
HIV-infected patients. The study was underpowered to
detect small differences in diagnostic accuracy measures
amongst different CD4 strata. Descriptive statistics were
used to characterise the study population. Diagnostic ac-
curacy measures presented include sensitivity, specificity,
positive (LR+, PPV) and negative (LR-, NPV) likelihood
ratios and predictive values all with 95 % confidence inter-
vals (CI). χ2 and Fisher’s exact test with mid-P correction
were used for comparisons between proportions, and the
Mann-Whitney test was used to compare differences in
TBscore. The potential impact of same-day LAM testing
was assessed by assuming that LAM testing would be
performed at the first point of clinic contact and all LAM-
positive patients would initiate anti-TB treatment immedi-
ately. χ2-squared testing is used to compare same-day
treatment initiation and treatment dropout proportions
with and without the use of LAM in each study arm.
Multivariable- linear (for morbidity scores) and logistic
(for mortality) regression analyses were performed. Sam-
ple size calculations were based on the primary outcome
for the parent study [5] (http://clinicaltrials.gov/show/
NCT01554384). Based on the prevalence of HIV and
culture-positive TB cases in the parent study there was ad-
equate study power for the 95 % CI around LAM accuracy
measures to be within a range of ±10 %. Analyses were
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performed using OpenEpi (version 2.3.1) [23], and R (ver-
sion 3.0) [24]. The study is reported in accordance with
the STARD initiative recommendations [25].
Role of the funding source
Alere donated the LAM strip tests. However, neither the
company nor the study sponsor had any role in study
design, data collection, data analysis, data interpretation,
or writing of the report. The corresponding author had
full access to all the data in the study and had final re-
sponsibility for the decision to submit for publication.
Results
Study sites and population characteristics
Figure 1 provides the study profile. We enrolled 1095
patients with suspected TB, that were able to provide ≥2
sputa and a spot urine sample, from four primary care
clinics in South Africa (n = 419 in Cape Town, n = 193 in
Durban), Zambia (n = 400) and Tanzania (n = 83). Fur-
ther detailed descriptions of each primary care clinic
have already been published with the parent study [5].
HIV-infection was confirmed in 564/1095 (52 %) and test-
ing was refused in 19/1095 (1 %); LAM test performance
is considered in these two groups combined (N = 583). Of
the 583 HIV-positive/status unknown patients with sus-
pected TB, 14 (2 %) had either a contaminated culture or
no available result, and 181 (31 %) had culture-positive
TB. Table 1 provides the basic demographic and clinical
characteristics of the HIV-infected patients of the study
population stratified by study site.
LAM performance
Three (<1 %) LAM strip tests failed on the first attempt
and required use of a second strip test to produce valid
results. The 3rd LAM strip reader was required in 151/
583 (26 %) patients, and in 126/151 (83 %) cases this was
for differences in grading bands between the grade 0 and
1 intensity. Thus, excluding grade 0 /1 discordance a 3rd
reader was required in only 25/583 (4 %) of patients.
Additional file 1 Table S2 compares LAM diagnostic
accuracy using the grade-2 versus grade-1 cut-point
(pre-January 2014 reference card, Fig. 1A) showing the
higher specificity and LR+ of the grade-2 cut-point. Inter-
observer agreement as to the presence versus absence of
a test band of intensity grade 2 or higher was 97.3 %
(kappa 0.87), while agreement regarding the presence
versus absence of a test band of intensity grade 1 or
higher was 90.9 % (kappa 0.77), p < 0.001. Based on this
data, and previously published work [14–16, 26] and in
accordance with the updated manufacturer’s reference
card (see Additional file 1 Figure S1B), the remaining
diagnostic accuracy data presented in the results section
is presented using the grade-2 LAM cut-point.
Table 2 shows the diagnostic accuracy of LAM, Xpert
MTB/RIF and smear-microscopy amongst HIV-infected
patients stratified by CD4 cell count (PPV, NPV, LR+
and LR- shown in Additional file 1 Table S3). Overall,
LAM had sensitivity (95 % CI) and specificity (95 % CI)
of 22.7 % (16.6–28.7) and 93.0 (90.5–95.6) respectively.
LAM specificity did not significantly increase when TB
culture-negative patients diagnosed with clinical-TB
Fig. 1 Study profile. §LAM testing is not indicated for HIV uninfected patients. #The 19 patients with refusing HIV testing and hence with
unknown HIV status are included with HIV-infected patients for the evaluation of LAM performance and potential impact on TB-related morbidity
given that this would occur in routine clinical practice. ¶ Clinical TB includes any culture-negative patient given anti-tuberculosis treatment (at any
point during the 6 month study period) based on either a sputum-positive Xpert MTB/RIF (n = 14) or smear microscopy (n = 11) result, a Chest
x-ray suggestive of TB (n = 96) or clinical suspicion alone (n = 6). *1 Smear-positive culture-negative patient did not receive anti-TB treatment
and is thus not considered as “Clinical TB diagnosed and treated”. Results of LAM are provided in italics because they were not used for
treatment decisions
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were considered reference test positive in a secondary
analysis [95.4 % (92.1–97.4) versus 93.0 (90.5–95.6), p =
0.2, Additional file 1 Table S4]. LAM specificity was sig-
nificantly higher at South African compared to Zambian
and Tanzanian study sites, both in the primary and sec-
ondary analyses [Primary analysis: Cape Town: 99.0 %
and Durban: 97.9 % compared to Lusaka: 87.1 % and
Mbeya: 89.7 %, p < 0.001 for comparisons between SA
sites and Lusaka and p < 0.05 for comparisons between
SA sites and Mbeya] (see online Additional file 1 Table
S5B and C)]. LAM strip sensitivity (95 % CI) was not
significantly higher in CD4 ≤ 100 versus >100cell/mm3
[30.4 % (17.1–43.7) versus 18.3 % (12.5–25.9), p = 0.085],
while specificity was similar.
LAM testing compared to Xpert MTB/RIF or smear
microscopy
The overall sensitivity (95 % CI) of Xpert MTB/RIF
(76.1 %, 70/92) was significantly higher than either LAM
(22.7 %, 41/181) or smear microscopy (43.8 %, 39/89)
(p < 0.001 for both comparisons); similarly in patients with
CD4 ≤ 100 cells/mm3 Xpert MTB/RIF (76.2 %, 16/21)
offered higher sensitivity than either LAM (30.4 %, 14/46,
p < 0.001) or smear microscopy (36 %, 9/25, p = 0.006).
Xpert MTB/RIF had the highest test LR+ (95 % CI) of 10.7
(9.2–12.4) and correspondingly a PPV (95 % CI) of 83.3 %
(74.0–89.8). Overall, but not in patients with CD4 ≤ 100
cells/mm3, smear microscopy (43.8 %, 39/89) offered sig-
nificantly higher sensitivity compared to LAM alone
(22.7 %, 41/181, p < 0.001). Similar differences in test sensi-
tivities were seen across all study sites except in Durban
where LAM (40 %), sputum Xpert MTB/RIF (60 %) and
smear microscopy (50 %) offered similar sensitivities
(online Additional file 1 Table S5A). Specificity of LAM
(93.0 %), Xpert MTB/RIF (92.9 %) and smear microscopy
(93.2 %) used alone was similar irrespective of CD4 strata
(p > 0.05 for all comparisons).
LAM in combination with either sputum-based MTB/RIF
or smear microscopy
The diagnostic accuracy of using LAM in combination
with either sputum-based Xpert MTB/RIF or smear-
microscopy is also shown in Table 2. LAM plus Xpert
MTB/RIF (72/92, 78.3 %) did not offer significantly better
sensitivity to Xpert MTB/RIF alone (70/92, 76.1 %) (p = 0.7).
Similarly, LAM plus smear microscopy (50/89, 56.2 %) did
not offer significantly better sensitivity to smear microscopy
alone (39/89, 43.8 %) (p = 0.1). In contrast, the specificity of
Table 1 Study site and population characteristics
Gugulethu TB Clinic
(Cape Town, South Africa)
Kanyama TB Clinic
(Lusaka, Zambia)





No. patients enrolled in parent RCT 419 400 193 83 1095
HIV-infected 133 (32) 268 (67) 114 (59) 49 (59) 564 (52)
HIV uninfected 278 (66) 130 (33) 70 (35) 34 (41) 512 (47)
HIV testing refused 8 (2) 2 (<1) 9 (5) 0 (0) 19 (1)
Demographics of HIV-infected/testing refused patients included in primary analysis (N = 583)
N = 141 N = 270 N = 123 N = 49 N = 583
Median age, years (range, IQR) 35 (19-79, 30-40) 35 (19-79, 30-40) 36 (20-63, 29-42) 36 (17-72, 33-48) 36 (17-79, 30-41)
Women (%)a 81 (58) 99 (37) 65 (53) 27 (55) 272 (46)
Previous TBb (%) 69 (49) 42 (16) 37 (30) 2 (4) 150 (26)
Median CD4 cell count, cells/ml
(range, IQR)c
261 (6-1089, 137-410) 201 (1-1251, 104-339) 231 (2-1157, 106-494) 91 (1-423, 33-213) 210 (1-1251, 103-375)




39 (28) 100 (37) 25 (20) 17 (35) 181 (31)
Clinical TBf (%) 17 (12) 26 (10) 6 (5) 4 (8) 53 (9)
TB-related morbidity at baseline in culture-positive patients
Median TBscore (IQR)g 4 (3-5) 6 (4-7) 5 (4-6) 7 (5-9) 5 (4-7)
Abbreviations: IQR, interquartile range; TB, tuberculosis
Footnotes:aA smaller proportion of patients in Lusaka were female compared to Cape Town, Durban and Mbeya (p-values of <0.0001, 0.003, and 0.015)
bA greater proportion of patients in Cape Town had a history of previous TB compared to Lusaka, Durban, and Mbeya (p-values of <0.0001, 0.002, and <0.0001)
cHIV-infected patients in Mbeya had lower CD4 cell counts compared with Cape Town, Lusaka and Durban (p-value of <0.001 for all comparisons)
dA greater proportion of HIV-infected patients were on ART in Cape Town compared to Lusaka, Durban, and Mbeya (p-value of <0.0001 for all comparisons)
eA lower proportion of patients in Durban were culture-positive for TB compared to Lusaka and Mbeya (p-values <0.001 and 0.05)
fThe median TBscore in patients from Mbeya was higher than Cape Town, Lusaka or Durban (p-values <0.0001 for all comparisons)
gA greater proportion of patients culture-negative patients received TB treatment empirically in Cape Town compared to Durban (p = 0.039)
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LAM plus Xpert MTB/RIF (169/196, 86.2 %) was signifi-
cantly lower than either LAM strip (361/388, 93.0 %) or
Xpert MTB/RIF (182/189, 92.9 %) testing alone (p = 0.007
versus LAM and p = 0.032 versus Xpert MTB/RIF), and
these relationships were unchanged if the analysis was
restricted to patients with CD4 ≤ 100 cells/mm3. For LAM
plus smear microscopy, the overall specificity (172/192,
89.6 %) did not differ significantly compared to either LAM
(361/388, 93.0 %) or smear (179/192, 93.2 %) alone (p > 0.05
for both comparisons), however, in patients with CD4 ≤
100 cells/mm3 combined specificity was lower than LAM
testing alone (93.0 %) (p = 0.037). The specificity relation-
ships were unchanged in the secondary analysis (Additional
file 1 Table S4).
A sensitivity analysis was performed to investigate the
impact of the 21 % (28/131) and 27 % (36/130) Non-TB
patients in the smear and Xpert study arms respectively
that were lost-to-follow up and the 1.5 % (2/131) and 3 %
(4/130) that were deceased. No differences in the diag-
nostic accuracy of LAM alone or with smear/Xpert were
noted (data not shown).
Potential impact on patient-important treatment
outcomes of adding point-of-care LAM to sputum-based
Xpert MTB/RIF or smear microscopy
In the parent study, the reason for treatment initiation,
time-to-treatment and failure to initiate treatment in
culture-positive TB patients (‘dropout’) was recorded
(Fig. 2). The potential impact on these outcomes of add-
ing point-of-care LAM (in the manner described in
methods section) is also shown in Fig. 2. In the smear
microscopy study arm with the use of empiric treatment
based on CXR, use of POC LAM would neither have
significantly decreased dropout [18 % (16/89) to 12 %
(11/89), p = 0.3], nor significantly increased same-day
treatment initiation [35 % (31/89) to 44 % (39/89), p =
0.2]. However, in primary care settings without same-day
CXR facilities, POC LAM would have significantly in-
creased same-day treatment initiation [24 % (21/89) to
44 % (39/89, p = 0.004]. Potentially unnecessary treat-
ment initiation would have increased by 3 % (4/116) due
to LAM ‘false-positives’. In the Xpert MTB/RIF study
arm, LAM would neither have significantly decreased
Table 2 Key diagnostic accuracy measures of LAM (grade 2 cut-point), sputum Xpert MTB/RIF or smear microscopy alone or in
combination for culture-confirmed versus culture-negative pulmonary tuberculosis amongst HIV-infected (and refused testing)
patients stratified by CD4 cell count
Diagnostic (s) Sensitivity Specificity
n/N % (95% CI) n/N % (95% CI)
LAM alonea
HIV-infected 41/181 22.7 (16.6-28.7) 361/388 93.0 (90.5-95.6)
CD4≤ 100 cells/mm3 b 14/46 30.4 (17.1-43.7) 70/75 93.3 (87.7-99.0)
CD4 > 100 cells/mm3 23/126 18.3 (12.5-25.9) 257/274 93.8 (90.3-96.1)
Xpert MTB/RIF alone
HIV-infected 70/92 76.1 (67.4-84.8) 182/196 92.9 (88.4-95.7)
CD4≤ 100 cells/mm3 16/21 76.2 (58.0-94.4) 36/40 90.0 (80.7-99.3)
CD4 > 100 cells/mm3 47/63 74.6 (62.7-83.7) 130/138 94.2 (89.0-97.0)
Smear alone
HIV-infected 39/89 43.8 (34.0-54.2) 179/192 93.2 (88.8-96.0)
CD4≤ 100 cells/mm3 9/25 36.0 (17.2-54.8) 31/35 88.9 (78.6-99.1)
CD4 > 100 cells/mm3 30/63 47.6 (35.8-59.7) 129/136 94.9 (89.8-97.5)
Xpert MTB/RIF and LAM combinedc
HIV-infected 72/92 78.3 (69.8-86.7) 169/196 86.2 (81.4-91.0)
CD4≤ 100 cells/mm3 18/21 85.7 (70.7-100.1) 35/40 87.5 (77.3-97.7)
CD4 > 100 cells/mm3 47/63 74.6 (62.7-83.7) 121/138 87.7 (81.2-92.2)
Smear and LAM combinedc
HIV-infected 50/89 56.2 (45.9-66.5) 172/192 89.6 (85.3-93.9)
CD4≤ 100 cells/mm3 11/25 44.0 (24.5-63.5) 28/35 80.0 (66.7-93.3)
CD4 > 100 cells/mm3 38/63 60.3 (48.0-71.5) 125/136 91.9 (86.1-95.4)
a14/583 HIV-infected and test refused patients had no reference standard result (see Fig. 1) and therefore a total of 569 patients were used for evaluation of
urinary LAM performance
b48/569 HIV-infected patients with LAM test results missing CD4 cell count data. For no diagnostic accuracy measure did any of the diagnostic tests, either alone
or in combination, performed significantly better in CD4 ≤ 100 cells/mm3 compared to CD4 > 100 cells/mm3 (p > 0.05)
cEither test positive is considered as a “positive” result
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treatment dropout [11 % (10/92) to 10 % (9/92), p = 0.8]
nor significantly increased same-day treatment initiation
[55 % (51/92) to 57 % (52/92), p = 0.9]. However, poten-
tially unnecessary treatment initiation would have in-
creased by 7 % (7/106) due to LAM ‘false-positives’.
LAM as a potential prognostic marker
Table 3 shows all cause 6-month mortality, lost-to-follow-
up and TBscore at enrolment amongst HIV-infected/sta-
tus unknown patients stratified by LAM result. LAM strip
positive versus negative patients had: i) higher all cause
6-month mortality [25 % versus 11 %, P = 0.02], ii) higher
lost-to-follow-up [54 % versus 30 %, p < 0.001], and iii) a
higher baseline TB-related morbidity score [7 (6–8) versus
5 (4–7), p = 0.03]. However, in the multivariate analyses
shown in Table 4, LAM positivity was only a predictor
of the combined outcome of lost-to-follow-up/death but
not 6-month mortality or baseline TBscore. In addition,
TB-related morbidity outcomes, as measured by the
amount of improvement from enrolment in TB-score at
2- and 6-months post-initiation of effective anti-TB
treatment were similar amongst LAM strip positive ver-
sus negative patients [4(3–5) versus 4 (2.5–5), p = 0.136]
(online Additional file 1 Table S6).
Discussion
In this multi-centre out-patient study of patients with
suspected PTB able to provide expectorated sputum for
diagnostic testing, LAM had poor overall sensitivity,
which did not significantly improve in patients with
CD4 cell counts less than 100 cells/ml. LAM was not
able to improve on the diagnosis offered by either spu-
tum-based Xpert MTB/RIF or smear microscopy alone.
Due to this lack of incremental utility over sputum-based
Fig. 2 Treatment outcomes in each study arm indicating the potential impact of LAM in TB culture positive patients. a Smear-microscopy
b clinic-based Xpert MTB/RIF testing. ‘False-positives’: These indicate patients that were sputum culture-negative, smear or Xpert MTB/RIF-negative
and not given empiric TB treatment by the attending clinician that would have been LAM positive. These patients would have thus received
inappropriate anti-TB treatment
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tools, LAM seems unlikely to be able to improve outpatient
important treatment outcomes. Indeed, although LAM
could offer some prognostic utility in identifying patients at
high risk of death or loss-to-follow-up, there was no impact
on patient dropout or morbidity. Adjunctive LAM testing
may only increase same-day treatment initiation in clinic
settings using sputum smear microscopy where same-day
chest radiography is not available to guide empiric same-
day treatment decisions. It may be argued that our study
only considered outpatients able to expectorate sputum,
and LAM may offer important incremental value for pa-
tients unable to provide sputum for diagnostic testing.
However, this study’s patient population is the major
subgroup presenting to primary care facilities for front-
line testing and although preliminary data suggest that
this is not the subgroup most likely to benefit from
LAM, data is nevertheless essential for clear recommen-
dations to guide implementation across TB programs.
Indeed, program directors continue to question why the
only commercially available and affordable POC TB test
is unavailable for frontline testing? The data outlined
here offers valuable insights.
Published data, albeit limited, indicate that LAM sen-
sitivity is increased with higher circulating LAM levels,
occurring with higher mycobacterial disease burden,
extrapulmonary TB, lower CD4 cell count and WHO
clinical stage 3 and 4 in out- and in-patient settings [11,
27–34]. Moreover, LAM and sputum smear microscopy
identified non-overlapping sub-groups of culture-positive
TB, thereby offering additive diagnostic value [11–14, 16,
35]. By contrast, we found no incremental benefit of
LAM. There are a number of possible explanations.
Firstly, sputum-scarce TB, smear-negative TB, and EPTB
is more common in hospital-based and pre-ART screening
cohorts and thus smear microscopy sensitivity is more
likely to be reduced, which in turn would increase the
incremental benefit offered by LAM testing. Secondly, dif-
ferences in sputum smear microscopy staining and con-
centration methodologies across different studies affect
smear microscopy sensitivity [13]. Thirdly, in contrast to
other LAM-based studies [11, 12, 14] our study did not
offer sputum induction to improve sputum sampling and
thus, those unable to spontaneously produce two spot
sputa were excluded. Sputum induction was not offered as
the pragmatic study design of the parent study reflects the
reality that sputum induction facilities remain unavailable
in the majority of routine primary care clinic settings.
Nevertheless, the inability of LAM testing to improve the
diagnostic yield of a single sputum-based Xpert MTB/RIF,
irrespective of declining CD4 cell count, is consistent with
the findings of Lawn et al. and reflect the superior sensi-
tivity of sputum-based Xpert MTB/RIF for the diagnosis
of pulmonary TB [11, 36, 37].
In our initial study of LAM amongst hospitalised HIV-
infected patients with advanced immunosuppression we
noted that test specificity and inter-reader agreement was
optimised (>95 % for both) by use of an alternative grade-2
rather than the manufacturer’s initially suggested grade-1
cut-point [16]. Based on these findings, the manufacturer’s
reference card has been updated as of January 2014 so that
the first positive visual band corresponds to the grade-2
intensity band of the old reference card (see Fig. 1 of the
online supplement, www.alere.com).
Independent of cut-point selection, suboptimal LAM
specificity (<95 % as recommended by an expert commit-
tee for point-of-care TB testing [38]), particularly in
countries north of South Africa, remains a concern. In-
deed we noted lower test specificity in Tanzania and
Zambia compared to the two South African study sites.
Reasons for this may include different degrees of the un-
avoidable misclassification bias associated with a single
sputum culture to correctly classify TB in HIV-infected
patients with advancing immunosuppression. However,
in our secondary analysis excluding ‘probable or clinical
TB’ the specificity in Zambia and Mbeya remained
lower. Kroidl et al. found cross-contamination of the
LAM ELISA from dust, soil and stool in Tanzania, and
we have demonstrated cross-reacting LAM-like glyco-
lipid antigens in Nocardia and Candida spp. [30, 39].
Sterile collection of urine samples is essential, especially
Table 3 Morbidity (measured by TBscore), 6-month all cause mortality and lost-to-follow up stratified by baseline results of LAM in
HIV-infected (or test refused) patientsa
All HIV-infected n/N (%) LAM strip positive n/N (%) LAM strip negative n/N (%) P-value
6-month mortality (N = 393)b 49/393 (13) 9/32 (25) 40/361 (11) 0.021
TB culture-positive only (N = 123)b 6/17 (35) 15/106 (14) 0.032
Lost-to-follow up 190/583 (33) 38 (54) 152 (30) <0.001
Culture-positive (N = 58) 24/41 (59) 34/140 (24) <0.001
TBscore at enrolment
Culture-positive (N = 181) 6 (4-7.5) 7 (6-8) 5 (4-7) 0.025
a14 HIV-infected and test refused patients with no reference standard result (see Fig. 1) excluded from the analyses of index test diagnostic accuracy are included
in this analysis of morbidity and mortality. Thus a total of 583 patients are included in this table’s analysis
bOf the 583 HIV-infected patients with a LAM result, 190 were lost-to-follow-up at 6-months. Of the 393 patients with complete 6-month follow-up data, 123 were
culture-positive TB
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in countries north of South Africa, and in a recent
Ugandan in- and out-patient study LAM specificity was
95 % [14].
LAM offered limited incremental diagnostic benefit
over sputum-based diagnostics. In contrast to studies
showing incremental benefit of LAM in hospitalised pa-
tients with sputum-scarce TB and EPTB [14, 16] or
those identifying patients with TB missed by empiric
treatment initiation but identified by LAM [40]. Conse-
quently, our study suggests LAM would have minimal
potential impact on patient important treatment out-
comes. In fact, test specificity was significantly lower
when combining Xpert MTB/RIF with LAM for both a
culture and composite reference standard with the po-
tential to increase inappropriate treatment initiation.
Thus, sputum-based diagnosis, especially where Xpert
MTB/RIF is available, should be preferred in HIV-
infected outpatients able to spontaneously provide sputa.
However, LAM may potentially improve same-day treat-
ment initiation in the clinic setting where only sputum
smear microscopy is performed and no chest radiog-
raphy facilities are available. In addition, LAM may still
offer i) important added diagnostic benefit where the
performance of sputum-based tests is reduced such as
Table 4 Multivariate analysis showing predictors of all-cause mortality, lost-to-follow-up/mortality and baseline TB-related morbidity
in HIV-infected patients overall and restricted to culture-positive TB patients onlya
P-value AOR Lower 95 % CI Upper 95 % CI
6-month all-cause mortality
All HIV-infected (n* = 173)
Age, years 0.051 0.934 0.867 0.997
CD4 cell count, cells/mm3 0.038 0.996 0.991 0.999
TB culture positive (pos/neg) 0.007 9.207 2.069 53.4
Baseline TB score 0.050 1.349 1.012 1.86
LAM strip resultb 0.170 2.762 0.613 11.72
TB culture positive (n = 117)
CD4 cell count, cells/mm3 0.069 0.9951 0.989 0.999
Baseline TB score 0.007 1.683 1.19 2.555
LAM strip result 0.252 2.59 0.495 13.72
Lost-to-follow-up or deceased
All HIV-infected (n = 268)
Age, years 0.048 0.966 0.932 0.999
Zambia <0.0001 12.52 4.077 45.15
Durban, South Africa 0.052 3.701 1.027 14.82
CD4 cell count, cells/mm3 0.058 0.998 0.997 1
LAM strip result 0.002 4.382 1.834 11.58
TB culture positive (n = 170)
Age, years 0.010 0.944 0.903 0.985
Zambia 0.002 5.897 2.055 18.61
Baseline TB score 0.006 1.301 1.085 1.583
LAM strip result 0.007 4.717 1.638 15.85
Baseline TB score (n = 146)
TB culture positive
CD4 cell count, cells/mm3 0.02716 0.9977 0.9958 0.9997
LAM strip result (pos/neg) 0.1771 1.886 0.7542 4.717
Abbreviations: ARV, anti-retroviral; CI, confidence interval; AOR, adjusted odds ratio
aAdditional co-variates included all multivariate models as potential confounders include: study arm (Xpert MTB/RIF or smear), study site, sex, age. Additional
co-variates evaluated as additional predictors of outcomes included: positive initial TB result (Xpert MTB/RIF or smear), ARV treatment status, previous TB and CXR
suggestive of TB. LAM strip test is always shown while only significant co-variates in each multivariate regression are shown
*n = number included in each of the multivariate models depending on outcome and sub-group considered
bLAM strip results are considered as a binary variable (positive/negative) using the grade 2 cut-point. Results of the multivariate analysis do not change if LAM
strip results are considered as continuous variable from grade 0-5
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sputum-scarce TB, extrapulmonary TB, mycobacteremia
[27], and/ or renal TB [41], and ii) important prognostic
and treatment monitoring utility [18].
This study had several limitations and strengths. It is
the first large multicentre study in primary care practice,
allowing for accurate evaluation of diagnostic accuracy
across three sub-Saharan African countries. The design of
the parent study offered a unique opportunity to evaluate
the diagnostic accuracy of LAM in a well-defined out-
patient population able to provide sputum for diagnostic
testing and hence, to estimate the potential impact of
LAM when combined with either Xpert MTB/RIF or
smear in this patient group. Misclassification bias was a
potential problem in our study as a single sputum culture
can miss TB cases amongst HIV-infected patients. How-
ever, in an alternative analysis where TB culture-negative
patients diagnosed as clinical TB and initiating treatment
are considered the reference test, no significant difference
in LAM specificity was noted and study conclusions were
unaltered. In addition, a sensitivity analysis with lost-
to-follow-up and deceased patients excluded from the
non-TB group i.e. considered unclassifiable, did not sig-
nificantly alter diagnostic accuracy measures. LAM was
performed on frozen rather than fresh samples which could
have reduced test sensitivity, however, meta-analysis data
suggests no differences in diagnostic accuracy using frozen
rather than fresh samples [42]. Consequently, impact data
for adjunctive LAM is extrapolated. The study was not
powered to detect small differences in sub-groups (CD4
strata, treatment dropouts) and thus small incremental
benefits of LAM in these sub-groups may not have been
detected. Likewise, the small number of study deaths lim-
ited power to examine LAM as a predictor of mortality in
the multivariate analysis.
In conclusion, LAM strip testing had poor sensitivity
amongst HIV-infected outpatients able to provide expec-
torated sputum for diagnostic testing. There was no incre-
mental diagnostic benefit over either Xpert MTB/RIF or
smear microscopy. If used as an adjunctive diagnostic
tool in this setting, it is unlikely to impact patient-
important treatment outcomes such as morbidity, patient
dropout, or same-day treatment initiation, except in
smear microscopy only clinics with no chest radiography.
Potential gains need to be weighed against the likely
increase in inappropriate ‘false-positive’ treatment. How-
ever, further impact-orientated studies focused on mor-
tality and morbidity benefits in ill hospitalised patients
are warranted.
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